Clinical Trials
52 trialsStudy With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)
Helsinn Healthcare SA
APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer
Heron Therapeutics
Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer
University of Rochester
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Alliance for Clinical Trials in Oncology
Buccal Film Versus IV Injection Palonosetron for Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting
Xiamen LP Pharmaceutical Co., Ltd
ProTreat
University Hospital Freiburg
Effect of SAR302503 on ECG Activity in Patients With Solid Tumors
Bristol-Myers Squibb
Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy
Alliance for Clinical Trials in Oncology
Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP
Australasian Leukaemia and Lymphoma Group
CINV
Helsinn Healthcare SA
A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation
Icahn School of Medicine at Mount Sinai
Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer
M.D. Anderson Cancer Center
Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
CINV
Sun Yat-sen University
Buccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MEC
Xiamen LP Pharmaceutical Co., Ltd
TSEPHCC
Xijing Hospital
The Optimization of Antiemetic Regimen for C-RINV in LA-HNSCCs
ChineseAMS
An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting
Helsinn Healthcare SA
Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant
OHSU Knight Cancer Institute
Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer
M.D. Anderson Cancer Center
MEDEA
Amsterdam UMC, location VUmc
Intravenous Palonosetron With Radiotherapy and Concomitant Temozolomide
Duke University
Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy
Hoosier Cancer Research Network
GIM15-NEPA
Consorzio Oncotech
Effectiveness and Quality of Life Analysis of Palonosetron Against Ondansetron Combined With Dexamethasone and Fosaprepitant in Prevention of Acute and Delayed Emesis Associated to Chemotherapy Moderate and Highly Emetogenic in Breast Cancer.
Instituto Nacional de Cancerologia de Mexico
An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting
Helsinn Healthcare SA
RAPA
Kangdong Sacred Heart Hospital
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
Alliance for Clinical Trials in Oncology
Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer
University of Washington
Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX
OHSU Knight Cancer Institute
Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy
University of Washington
Palonosetron in Moderately and Highly Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04935)(COMPLETED)
Merck Sharp & Dohme LLC
Palonosetron Plus Dexamethasone in Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04594)
Merck Sharp & Dohme LLC
Multi-day Doses in Prevention of Nausea and Emesis
University of Kansas Medical Center
Safety and Efficacy Study for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving Stem Cell Transplantation.
Eisai Inc.
Efficacy of Thalidomide in Preventing Chemotherapy-induced Delayed Nausea and Vomiting
China Medical University, China
Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy
Zhejiang University
The Efficacy and Safety of Palonosetron in Preventing the Gastrointestinal Reactions Induced by 3-day Highly Emetogenic Chemotherapy
Jiangsu Simcere Pharmaceutical Co., Ltd.
Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial
University of Rochester
GAND-emesis
Odense University Hospital
Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Palonosetron in Cancer Treated With Chemotherapy
Clinica Universidad de Navarra, Universidad de Navarra
An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting
Helsinn Healthcare SA
Olanzapine Against Delayed Nausea and Vomiting in Women Receiving Carboplatin Plus Paclitaxel
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Aloxi for Prevention of Chemotherapy Induced Nausea and Vomiting in Malignant Glioma Patients Receiving Irinotecan With Bevacizumab
Duke University
Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)
Ohio State University Comprehensive Cancer Center
Palonosetron in Sarcoma Patients Receiving Chemotherapy With Adriamycin and Ifosfamide (AI)
M.D. Anderson Cancer Center
ESPNV
Shanghai Changzheng Hospital
Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting
M.D. Anderson Cancer Center
Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting
M.D. Anderson Cancer Center
NHLPal
Gruppo Italiano Studio Linfomi